Table 1.

Overview of literature for osimertinib-induced BRAF V600 mutation with the reported efficacy and treatment toxicities

Author	Cases	Baseline EGFR mutation	Previous treatment	Mutation profile at resistance to osimertinib	Treatment	Initial dose	Dose adjustment	Best overall response	Progression-free time	Adverse effect (grade)
Huang et al	65 male	EGFR 19del	Gefitinib→Osimertinib	EGFR 19del/T790M BRAF V600E	D + T + O	D:150 mg bid T:1 mg qd O:80 mg qd	Not need	SD	>7.4months	Diarrhea(G1) Aronychia(G1)
Solassol et al	68 female	EGFR 19del	Chemo→Afatinib→chemo→ICI→Osimertinib→chemo+anti-VEGF	EGFR 19del/T790M BRAF V600E	D + T + O	D:150 mg bid T:2 mg qd O:80 mg qd	Not need	SD	6 months	NR
Ding et al	63 male	EGFR 19del	Gefitinib→Osimertinib	EGFR 19del/T790M BRAF V600E	D + T + O	D:150 mg bid T:2 mg qd O:80 mg qd	Not need	SD	9 month	Pyrexia(G1-2) Arontchia(G1-2)
Zhou et al	69 male	EGFR L858R	Post-operative recurrence, gefitinib→chemo→osimertinib→chemo	EGFR L858R/T790M BRAF V600E	D + T + O	D:150 mg bid T:2 mg qd O:80 mg qd	Not need	PR	>2 months	Rash(G2) Decreased apptite(G2)
Meng et al	P1 : 56 female P2 : 66 male	P1:EGFR 19del P2:EGFR 19del	P1:Gefitinib→osimertinib P2:Afatinib→osimertinib	P1:EGFR 19del BRAF V600E P2:EGFR 19del/T790M BRAF V600E	P1: D + T + O P2: D + T + O	P1/P2: D:150 mg bid T:2 mg qd O:80 mg qd	P1:discontiuation P2:D:50 mg bid T:0.5 mg qd O:80 mg qd	/ PR	P1 : 6 weeks P2 : 13.4 months	P1:Pneumonitis P2:Pyrexia(G2) Nausea,vomiting
Ribeiro et al	50 female	EGFR 19del	Erlotinib→Osimertinib+SBRT→chemo+ICI→chemo	EGFR 19del/T790M BRAF V600E,PIK3CA mutation	D + T + O	D:75 mg bid T:1 mg qd O:80 mg qd	D:150 mg bid T:2 mg qd O:80 mg qd (Not succeed)	PR	8 months	Pyrexia,nausea dysgueusia(G1) Fatigue(G1→G2)
Mauclet et al	60 female	EGFR 19del	Chemo+WBRT→ICI→erlotinib→osimertinib	EGFR 19del/T790M BRAF V600E	D + T + O	D:150 mg bid T:2 mg qd O:80 mg qd	D:75 mg bid T:1 mg qd O:40 mg qd	PR	7 months	Increased creatine kinase(G3) Pyrexia(G2)

This table provides a summary of various literature sources that have investigated osimertinib-induced BRAF V600 mutation. It includes information on the effectiveness of the treatment (efficacy) as well as the adverse effects and side effects experienced by patients during the course of the treatment (treatment toxicities). The table serves as a comprehensive reference for understanding the outcomes and potential risks associated with osimertinib in relation to the specific BRAF V600 mutation.

Specific combination regimen, efficacy and toxicity of osimitinib-induced BRAF V600 mutations have been reported in the literature. (Concept adapted from Zeng et al. Cancer Drug Resist 2021;4 : 1019-27).

D, dabrafenib; O, osimertinib; T, trametinib.